Introduction

In 2018 the GLOBOCAN cancer database estimates there were almost 550,000 new bladder cancer cases recorded worldwide with 199,000-bladder cancer related deaths (1), making bladder cancer the 11th most common cancer worldwide. Approximately 25% of new bladder cancer cases present with muscle-invasive disease (2). Radical cystectomy (RC), pelvic lymph node dissection (PLND) and urinary diversion (UD) is the “Gold standard” surgical treatment for muscle-invasive bladder cancer (MIBC) and certain high risk or treatment refractory non-muscle invasive bladder cancers. Whilst open radical cystectomy (ORC) dates back to the 1800’s, creation of an ileal conduit is a more recent development first popularised by Bricker in the 1950’s (3). Today there are a variety of surgical techniques including ORC, laparoscopic radical cystectomy (LRC), robotic-assisted radical cystectomy (RARC), intra-corporeal urinary diversion (ICUD), extra-corporeal urinary diversion (ECUD) and bladder substitution with orthotopic neobladder.

ORC is a complex surgical procedure associated with high morbidity; complication rates range from 30–70% (4). LRC was introduced to mitigate against the morbidity associated with open surgery, however due to the prolonged learning curve and technically challenging procedure it failed to reach wide-spread adoption. RARC with its superior optics, increased dexterity and appealing ergonomics has largely superseded LRC as the principal minimally invasive surgical option. The adoption of RARC over the last 15–20 years has been impressive with a 25-fold increase in the US from 0.7% in 2002 to 18.5% in 2012 (5). Comparative studies and meta-analysis have shown equivalent oncological outcomes (6) with improvements in perioperative markers of surgical quality such as transfusion rates and length of stay (7). To date the majority of randomised control studies (RCTs) assessing RARC have
only included RARC with ECUD. This hybrid approach may diminish some of benefits of the purely minimally invasive surgery seen in ICUD.

This review focuses on the available evidence for RARC providing comparison on oncological, perioperative, functional, surgeon-specific and cost outcomes. A section is dedicated to the evidence for ICUD and its role within robotic cystectomy.

Oncological outcomes

The recently reported RAZOR trial (8) is the only RCT with a primary outcome comparing oncological outcomes of ORC vs. RARC. This multi-institute phase-3 non-inferiority trial found no inferiority of RARC compared to ORC in 2-year progression-free survival rates (RARC: 71.6% and ORC: 72.3%, Pnon-inferiority =0.001). Furthermore, similar 2-year survival outcomes were reported in several retrospective analyses (9,10). Admittedly, the 2-year follow-up period appears short in the RAZOR trial, however several studies reveal that 2-year follow-up is adequate to identify up to 81% of recurrences (11,12). Bochner et al.’s RCT (13) provides longer-term oncological outcomes with 5-year follow-up and found no statistical difference in recurrence-free, cancer-specific and overall survival when comparing ORC with RARC, albeit this was a small (n=118) single-institute RCT. Three other RCTs have used lymph node yields and positive surgical margin status as markers of oncological outcomes and found no statistical difference between ORC and RARC (14-16). Table 1 provides a description and comparison of the five RCTs comparing RARC with ORC.

The International Robotic Cystectomy Consortium (IRCC) multi-institute prospective database on RARC reports the longest follow-up period for oncological outcomes of RARC. Their recently published 2019 study provides 10-year follow-up and notes 10-year recurrence-free, disease specific and overall survival rates of 59%, 65% and 35% respectively, comparable to similar open series (17).

The significance of patterns of recurrence when comparing ORC and RARC is somewhat controversial. Initially there were concerns that RARC leads to tumour spillage, inadequate extirpation and dissemination of tumour cells. Nguyen et al.’s (18) retrospective analysis found no difference in the rates of local and distant recurrence rates between ORC and RARC but noted a difference in the pattern of distant recurrences. A higher rate of peritoneal carcinomatosis was seen in the RARC group (RARC 21% vs. ORC 8%) and a higher rate of recurrence in the extraperitoneal lymph nodes (ORC 15% vs. RARC 23%).

It is implied that higher rates of recurrence within the extra-pelvic lymph nodes may be due to less comprehensive lymph node dissection during the robotic procedure, despite the lymph node yields being the similar between the surgical modalities (median ORC node yield: 20, median node RARC yield: 21). It is postulated the higher peritoneal carcinomatosis seen in the robotic procedure may be due to tumour dispersion from the pneumoperitoneum. It is important to note that no statistical analysis was applied to these patterns of recurrence in Nguyen’s study leading to recent criticism (19). Secondary analysis of Bochner et al.’s 2015 RCT (13) found a similar propensity to local/regional first recurrence in the RARC group. In contrast the RAZOR trial (8) did not find any difference in rates of peritoneal carcinomatosis when comparing RARC with ORC. Furthermore, Tan et al.’s (20) retrospective analysis of ORC versus RARC with ICUD found no statistical difference in the rate or pattern of recurrence between the modalities. Corroborated by Collins et al.’s (21) multi-institute series, noting no difference in recurrence patterns and leading the author to assert that tumour biology had a greater impact on recurrence rates and patterns than surgical modality.

Major/minor complications

RC is a complex procedure performed in elderly, often highly co-morbid, patients resulting in significant morbidity. The Clavien-Dindo (CD) system (22) is used for reporting complications. CD 3–5 grades are considered major complications and CD 1–2 grades minor complications. The 5 RCTs comparing ORC with RARC all report on complications. Nix et al.’s (15) did not differentiate between major and minor complications but found no significant difference in absolute number of complications; 7 (33%) in the RARC group and 10 (50%) in the ORC group (P=0.2789) or in the mean CD grade, 2.3 and 2.6, respectively (P=0.5622). Messer et al.’s (16) pilot prospective RCT did not report minor CD 1 complications and reported transfusion as a separate complication but found no statistical difference between RARC and ORC for CD 3–5 complications, albeit this was a small study (n=40) with primary outcome measuring health-related quality of life (HRQoL). The CORAL study (14), a single-centre 3-arm RCT comparing 30- and 90- day complications rates for ORC, LRC and RARC hypothesised that due to “the
<table>
<thead>
<tr>
<th>Study</th>
<th>Trial type</th>
<th>Intervention</th>
<th>Number (n)</th>
<th>Urinary diversion</th>
<th>Complication rate (%)</th>
<th>Estimate blood loss (mL)</th>
<th>Operating time (min)</th>
<th>Length of stay (days)</th>
<th>Positive margin rate</th>
<th>Lymph node yield</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nix et al. 2010</td>
<td>Randomised noninferiority single-centre study 2008–2009</td>
<td>RARC</td>
<td>21</td>
<td>ECUD</td>
<td>33%</td>
<td>252</td>
<td>252</td>
<td>5.4</td>
<td>0%</td>
<td>19</td>
<td>(15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ORC</td>
<td>20</td>
<td>ECUD</td>
<td>50%</td>
<td>210</td>
<td>210</td>
<td>6</td>
<td>0%</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Messer et al. 2014</td>
<td>Pilot randomised control trial July 2009 to June 2011</td>
<td>RARC</td>
<td>20</td>
<td>Not specified</td>
<td>≥ CD 2: 25%</td>
<td>400</td>
<td>300</td>
<td>5</td>
<td>5%</td>
<td>11</td>
<td>(16)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ORC</td>
<td>20</td>
<td>Not specified</td>
<td>≥ CD 2: 25%</td>
<td>800</td>
<td>285</td>
<td>6</td>
<td>5%</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Bochner et al. 2015</td>
<td>Parallel RCT, expertise-based, superiority trial March 2010 to March 2013</td>
<td>RARC</td>
<td>60</td>
<td>ECUD</td>
<td>≥ CD 3: 22%</td>
<td>516</td>
<td>516</td>
<td>8</td>
<td>3.30%</td>
<td>Standard: 19.5, extended: 31.9</td>
<td>(13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ORC</td>
<td>58</td>
<td>ECUD</td>
<td>≥ CD 3: 21%</td>
<td>676</td>
<td>676</td>
<td>8</td>
<td>5.20%</td>
<td>Standard: 18.9, extended: 30</td>
<td></td>
</tr>
<tr>
<td>Khan et al. 2016 (CORAL)</td>
<td>Randomised controlled 3-arm parallel-group, expertise-based, superiority trial, single institute</td>
<td>RARC</td>
<td>20</td>
<td>ECUD</td>
<td>≥ CD 3: 35%</td>
<td>585</td>
<td>389</td>
<td>11.9</td>
<td>15%</td>
<td>16.3</td>
<td>(14)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LRC</td>
<td>19</td>
<td>ECUD</td>
<td>≥ CD 3: 11%</td>
<td>460</td>
<td>301</td>
<td>9.7</td>
<td>5%</td>
<td>15.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ORC</td>
<td>20</td>
<td>ECUD</td>
<td>≥ CD 3: 20%</td>
<td>808</td>
<td>293</td>
<td>14.4</td>
<td>10%</td>
<td>18.8</td>
<td></td>
</tr>
<tr>
<td>Parekh et al. 2018 (RAZOR)</td>
<td>Randomised multicentre (15 US institutions), open-label, randomised, phase 3, noninferiority trial</td>
<td>RARC</td>
<td>150</td>
<td>ECUD</td>
<td>≥ CD 3: 22%</td>
<td>300</td>
<td>428</td>
<td>6</td>
<td>6%</td>
<td>23.3</td>
<td>(8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ORC</td>
<td>152</td>
<td>ECUD</td>
<td>≥ CD 3: 22%</td>
<td>700</td>
<td>361</td>
<td>7</td>
<td>5%</td>
<td>25.7</td>
<td></td>
</tr>
</tbody>
</table>

RARC, robotic-assisted radical cystectomy; ORC, open radical cystectomy; ECUD, extra-corporeal urinary diversion; CD, Clavien-Dindo; LRC, laparoscopic radical cystectomy.
greater precision offered by robotic technology” RARC would reduce complication rates compared to the other two modalities. This hypothesis proved to be incorrect as the study found no significant difference in 30-day major (CD 3–5) complication rates between RARC and either ORC or LRC and, similarly, no significant difference in 90-day all grade complication rates between modalities. Bohner et al. (13) compared 90-day CD grade 2–5 complications and found no statistical difference between ORC and RARC, 66% and 62% respectively (P=0.7), meeting the trials futility criteria and facilitating early closure of the trial. More recently the RAZOR (8) trial found no significant different in 90 days all grade complication rates between ORC and RARC.

Meta-analysis and observational studies have revealed a mixed picture in regards to complication rates; Leow et al. (23) conducted a retrospective study of 279 hospitals including an impressive 34,672 patients undergoing ORC and 2,101 RARC patients. RARC was associated with 46% decreased odd of CD 1–2 complications (P=0.03) and no difference in CD 3–5 complications. Several early meta-analyses assessed complication rates; Tang et al. (24), Li et al. (25) and Fonseka et al. (26) all favoured RARC with significantly less perioperative complications when comparing RARC to ORC. Ishii et al. (27) found no difference in overall or CD 1–2 complications but found significantly more major complications in ORC. More recently, Shen et al. (28) and Tan et al. (29) found no statistical difference in CD 2–4 complications between the surgical techniques. Early meta-analyses were largely based on retrospective observational studies perhaps explaining the heterogeneity in published results.

**Perioperative outcomes**

Perioperative outcomes associated with quality of surgery including estimated blood loss, transfusion requirement, lengths of stay (LOS) and operating time have all been widely reported in RARC. Blood loss and transfusion requirement, in particular, have become the focus of renewed interest because several recent trials have noted an association between transfusion and worse survival outcomes. A 2016 meta-analysis of eight studies by Cata et al. (30) found blood transfusion was associated with a reduction of 27%, 29% and 12% in overall survival, cancer specific survival and recurrence free survival, respectively, in patients undergoing RC. Furthermore, Wang et al.’s (31) meta-analysis of 7,080 patients undergoing RC reported similar findings. Thus, the importance of blood loss and transfusion requirement may have been previously overlooked and highlights an area of possible advantage for RARC over ORC. Rai et al.’s (32) excellent Cochrane review, including the five aforementioned RARC vs. ORC RCTs, comprehensively applied the validated GRADE tool (33) to assess the quality of evidence and concluded with moderate certainty that RARC leads to substantially fewer blood transfusions (193 fewer transfusions per 1,000 RARC participants (95% CI: 262 fewer to 92 fewer) based on 460 transfusion per 1,000 participants for ORC). Sathianathen et al.’s (34) meta-analysis found a similar reduction in transfusion rates of 42% in the RARC group compared to ORC. The decrease in blood loss and transfusion requirement may largely be due to the tamponade effect seen with CO₂ insufflation and the benefit has been reproduced in meta-analysis comparing robotic prostatectomy versus open prostatectomy (35).

Operative time and length of stay vary significantly based on individual surgeon’s experience and particular institutions post-operative practices. Thus, reported data from single centre/surgeon trials may be of limited use. Protracted operative time is associated with poor outcomes such as venous thromboembolism and increased anaesthetic risk (36). Sathianathen et al. (34) found that RARC had significantly greater operative time compared to ORC with a mean difference of 68.51 min (95% CI: 30.55–105.48 min) and this increased operative time is consistently reported across the early literature. Increased operative time is perhaps offset by decreased LOS; all five RCTs provided data for LOS and cumulative analysis notes a modest mean reduction of 0.67 days for RARC over ORC (32). The introduction of the enhanced recovery protocol is likely to improve LOS irrespective of surgical modality and evidence has shown its benefit in other surgeries (37).

**HRQoL**

A diagnosis of MIBC leading to RC has a serious deleterious effect on the HRQoL of patients; first, a large proportion of patients undergo neo-adjuvant/adjuvant systemic therapy with associated debilitating side-effects, second, the surgery is highly morbid and third, patients face the psychological impact of managing life-long UD/ bladder substitution. A variety of HRQoL tools have been employed in the RC literature to date including the bladder cancer index (BCI), Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) and...
the European Organisation for the Research and Treatment of Cancer QOL core 30 (QLQ-C30) questionnaire. Four of the described RCTs provided data on QOL; Bochner et al. (13) utilised the non-bladder cancer specific QLQ-C30 questionnaire at baseline, 3- and 6-month intervals post-operatively and found no statistical difference in questionnaire scores between the modalities. More recently, the RAZOR trial (8) assessed HRQoL using the FACT-VCI questionnaire at baseline, 3- and 6-month and finding no statistical difference in survey scores between ORC and RARC.

A recent meta-analysis (38) assessing the effect of UD type on HRQoL found significant improvement in emotional functioning (85 vs. 79, P=0.023), cognitive functioning (93 vs. 85, P<0.001), constipation (16 vs. 31, P<0.001) and abdominal bloating flatulence scores (12 vs. 25, P<0.001) for ileal orthoptic neobladder compared to ileal conduit but the opposite for domains relating to sexual and urinary function. There are several criticisms of HRQoL research in RC, in part due to the heterogeneity of assessment tools making meaningful meta-analysis impossible. Furthermore, the majority of trials report the first post-operative assessment at 3 months negating the potential early benefit of RARC over ORC in terms of expedient return to normal activities. Analogous research (39) in colorectal surgery reveals statistically higher QoL scores at 2-week follow-up after minimally invasive bowel resection compared to the open approach perhaps highlighting the benefit of earlier post-operative recovery. Similarly, there is a lack of long-term HRQoL data for RARC and whilst we see follow-up periods approaching 10 years in robotic prostatectomy HRQoL studies (40), no such evidence exists in RARC.

**Surgeon-specific factors**

Almost all research on RC focuses on patient-specific outcomes and there is scant research on surgeon-specific outcomes besides learning curves. RC is a complex prolonged procedure, which requires great mental aptitude from the surgeon and thus surgeon-specific outcomes related to fatigue and efficiency are important considerations. Moore et al. (41) found that robotic systems allowed a shorter time to reach proficiency in surgical tasks and greater transferability of skills compared to laparoscopy. Multiple studies have shown surgeon stress has a deleterious effect on surgical performance (42). Novel work assessing cardiovascular parameters during stressful surgical tasks noted more favourable surgeon outcomes during robotic tasks compared to laparoscopic tasks (43). Abdelrahman et al.’s meta-analysis (44) noted indicators of workload, heart rate and reporting of musculoskeletal symptoms to be significantly less in robotic surgery compared to laparoscopic. However, there may be negative consequences of robotic surgery due to the increased demands on surgical assistants and poor communication due to the re-location of the primary surgeon away from the operating table to the surgical console (45). To the authors knowledge there are no comparative studies comparing ORC with RARC with respect to markers of surgeon stress or fatigue.

A variety of definitions for the learning curve exist but broadly speaking it is the time taken for a surgeon to achieve competence in a new procedure. The metrics used to gauge competency vary and importantly it pertains to the whole surgical team not just the primary surgeon. The Pasadena consensus panel (46) described the following parameters for surgical competence in RARC; estimated blood loss, operative time and positive surgical margin status. Hayn et al.’s (47) prospective study including 496 RARCs from 14 different institutes noted that operative time plateaued after just 21 procedures and acceptable lymph node yields and positive surgical margin status were achieved after 30 cases. Collins et al. (48) assessed the learning curve for their first 67 patients undergoing RARC with intracorporeal bladder substitute. The group noted a significant decrease in complications with increasing experience but no change in lymph node yield, LOS or estimated blood loss. Similarly, Richards et al. (49) noted significantly decreasing operating times and rates of complications over the duration of their 60-patient case series. For comparison, studies have shown a comparable learning curve for robotic partial nephrectomy with competency reached at 25–30 cases and plateauing at 70–75 cases (50). It is important to note that the majority of surgeons undertaking RARC have experience in robotic surgery through performing robotic prostatectomy and thus the learning curve might be somewhat abbreviated.

**Cost outcomes**

The comparison of cost between surgical modalities is fraught with difficulty due to a number of confounders; first of all there is much heterogeneity in the payment and public insurance systems between countries; second, the methods by which hospitals collect and report cost data varies widely; third, the assessment of indirect costs through re-admission and complications is often not included in cost analysis and
may not be representative of the cystectomy community as a whole. It is postulated that completely minimally invasive RC with IUCD may be advantageous due to smaller incisions, less post-operative pain, decreased bowel handling, decreased ureteric dissection leading to fewer stenosis and faster post-operative recovery (55).

Despite the potential benefits and increasing adoption of ICUD there is no level-1 evidence for its use; 4 of the 5 RCTs (8,13-15) assessing RARC only included patients with the hybrid ECUD approach, and the remaining RCT (16) did not comment on the UD approach taken. Hussein et al. (54) aforementioned study represents the largest retrospective study and noted less blood loss, fewer blood transfusions and shorter operative time (357 vs. 400 min) (P<0.001) in the IUCD group compared to the EUCD group. However, a greater tendency for complications in ICUD was noted, 57% vs. 43% (P<0.001). This may partly be explained by the surgeon’s learning curve because over time the rate of high grade complication in ICUD decreased; 25% in 2005 to 6% in 2015 (P<0.001), whilst the complicate rate for ECUD remained stable at 13–14% over the same time period representing prior surgeon experience with EUCD and plateauing of outcomes. Furthermore, a decreased operative time was seen in the ICUD group over the ECUD, 357 min (297–420 min) and 400 min (338–480 min) respectively (P<0.001). In contrast Bertolo et al. (56) conducted a single-institute prospective 2-arm comparative trial between RARC with ICUD vs. RARC with EUCD. They noted increased operative time in ICUD by 1 hour (P=0.0004) but comparable overall complication rates; ICUD: 26.7% vs. EUCD: 34.8%, (P=0.3).

Tan et al. (20) looked specifically at the short-term oncological outcomes for ORC vs. RARC with ICUD, including 184 patients with a mean follow-up of 33 months. The study found no significant difference in recurrence free survival, cancer specific survival, overall survival or pattern of recurrences between the two treatment modalities at 24 months. More recently, longer-term data is provided by Brassetti et al.’s (57) multi-institute retrospective study noting, 5-year recurrence free survival, cancer specific survival and overall survival probabilities were 58%±5%, 61%±5% and 54%±5%, respectively, comparable to RARC with EUCD.

Due to the greater technical difficulty and increased operative time for intra-corporeal bladder substitution
its adoption has been modest compared to ileal conduit; Hussein et al. (54) noticed an increased trend in intra-corporeal bladder substitution from 7% in 2005 to 17% in 2015. Several studies have published refinements on the initial technique first reported by Beecken and the Frankfurt group (58) in 2003. In 2010 Guru et al. (59) described the passing of a 1-0 silk “Keith” needle through the abdominal wall to suspend the ileal segment for creation of the intra-corporeal neobladder. Wiklund et al. (60) provides a detailed, illustrated step-by-step guide for intra-corporeal neobladder formation and Goh et al. (61) describes the innovative use of intra-venous indigo-cyanide with fluorescence enhanced imaging to identify mesenteric vessels when isolating the ileal segment.

Tostivint et al. (62) prospectively compared ORC and RARC with intra-corporeal bladder substitution noting decreased length of stay (median 12 vs. 17 days; P<0.05) and decreased blood transfusion (0 vs. 23.6%; P<0.05) in favour of RARC but increased operative time (median 360 vs. 300 min; P<0.001) and increased rate of uretero-ileal stenosis (25.5% vs. 23% P<0.05). Albeit, this was a small study (n=72) and the RARC arm only included 17 patients. Satkunasivam et al. (63) compared RC with intra-corporeal neobladder formation with the open approach, specifically assessing urodynamic and functional outcomes. The study included 107 patients and confirmed urodynamically that the creation of a low-pressure, high-volume neobladder with the robotic approach was feasible. Furthermore, HRQoL was measured using the BCI with no significant difference between the surgical approach, however the robotic approach was associated with worse day-time wetness and increased pad size albeit the follow-up period was shorter for the robotic group. Case series from Desai et al. (64) and Tyritzis et al. (11) further confirm the feasibility of intra-corporeal bladder substitution.

Robotic cutaneous continent bladder substitution is a nascent technique with literature largely pertaining to feasibility studies, small case series and description of technique; Goh et al. (65) first described the use of a modified “Indiana pouch” with a continent stoma created through a robotic port site. Desai et al. (66) provide a 10-patient case series for patients undergoing intra-corporeal robotic Indiana pouch continent cutaneous diversion with a mean operative time of 6 hours and major complication rate (CD >3) of 20% at 1 year. The use of a cutaneous continent mechanism is a fairly rare event even in ORC, however, the described case series are important because now the full gambit of open UD techniques have been replicated in the robotic setting.

Conclusion and future perspective

The feasibility of RARC is well established; the extirpative component largely has a bearing on oncological outcomes and, at the very least seems, comparable to ORC. Much of the morbidity in RC stems from the UD; ICUD may prove beneficial in reducing this morbidity and the technique is developing at a rapid pace. At present all types of open UD have been replicated robotically. It is hoped with continued technical refinements and improved surgical efficiency robotics will lead to the improved perioperative outcomes necessary to justify the increased cost, beyond merely the reduction in transfusion rates seen to date. Furthermore, with the anticipated expansion of choice in robotic systems, it is likely that competitive forces may decrease the cost or robotic surgery further broadening robotic surgery’s appeal. Current research is hampered by the expected limitations of conducting RCTs on surgical procedures. None of the described RCTs in this review assess the potential benefits of truly minimally invasive RARC with ICUD despite its widespread adoption. The ambitious iROC trial (NCT03049410), currently recruiting in the UK, aims to fill this research gap by reporting on oncological, perioperative, functional, surgical and cost outcomes for RARC with ICUD to hopefully provide the definitive answer on the optimal surgical technique for RC.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Ja Hyeon Ku, Ho Kyung Seo, Seok Ho Kang) for the series “Muscle-Invasive Bladder Cancer” published in Translational Andrology and Urology. The article has undergone external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2019.12.19). The series “Muscle-Invasive Bladder Cancer” was commissioned by the editorial office without any funding or sponsorship. Dr. Decaestecker reports personal fees and non-financial support from Intuitive Surgical, personal fees and non financial support
from Covidien, non-financial support from Conmed, personal fees and non-financial support from Ab Medica, personal fees and non-financial support from Cordamed Biomedical, personal fees and non-financial support from MSD, personal fees and non-financial support from Takeda, outside the submitted work. The authors have no other conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**

19. Pourmalek F, Abdi H, Black PC. Re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence...
44. Abdelrahman AM, Lowndes B, Rand C, et al. Impact of


